MedPath
HSA Approval

BETA - NICARDIA CAPSULE

SIN12389P

BETA - NICARDIA CAPSULE

BETA - NICARDIA CAPSULE

August 14, 2003

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Licence HolderSINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

C08CA55

nifedipine, combinations

Manufacturer Information

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

UNIQUE PHARMACEUTICALS LABORATORIES (A DIV OF J B CHEMICALS & PHARM LTD)

Active Ingredients

NIFEDIPINE

20 mg

Nifedipine

ATENOLOL

50 mg

Atenolol

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BETA - NICARDIA CAPSULE - HSA Approval | MedPath